Pluri CEO Letter: Turning Our Cell Technology and Experience into Commercial Opportunity
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Pluri (PLUR) outlined its commercial strategy around a signed ZEO ScientifiX agreement targeting expansion into the U.S. regenerative medicine market. Pluri expects to hold 50% of ZEO, subject to closing and transaction terms; completion and development of the combined platform remain ahead.
An entity beneficially owned by Chairman Alejandro Weinstein acquired Pluri's European Investment Bank loan effective November 4, 2026, releasing Pluri from EIB obligations. Separate loan-settlement agreements with that entity are expected. Pluri plans to expand CellaV distribution and grow recurring revenue through PluriCDMO. ISO 9001 and ISO 13485 certifications extend its service offerings. The PROTO Phase I trial of PLX-PAD for knee osteoarthritis completed its first step; the second is expected in January 2027, subject to a favorable safety review.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major pointPROTO collaboration received a €7.5 million non-dilutive grant under Horizon Europe to support the program.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Signed ZEO ScientifiX agreement supports planned U.S. expansion; Pluri expects a 50% holding, subject to closing and terms.
- Moderate pointEIB loan transfer closed November 4, 2026, releasing Pluri from obligations to the bank.
- Minor point. Forward-looking: it has not happened yet and may not happen.CellaV plans distribution expansion through physician-dispensed channels, clinics and partners, including ZEO in the U.S.
- Minor point. Forward-looking: it has not happened yet and may not happen.Pluri targets recurring revenue growth through PluriCDMO development and manufacturing services.
3 minor points
- Minor pointISO 9001 and ISO 13485 certifications enable offerings for current and new customers requiring those standards.
- Minor pointPROTO Phase I trial of PLX-PAD for knee osteoarthritis completed its first step.
- Minor point. Forward-looking: it has not happened yet and may not happen.Pluri is evaluating regulatory pathways, external funding and partnerships to advance selected therapeutic assets.
Negative
- Moderate point. Forward-looking: it has not happened yet and may not happen.ZEO transaction remains subject to closing; development of the combined commercial platform is still ahead.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Loan settlement with the chairman-owned acquiring entity remains subject to expected separate agreements.
- Minor point. Forward-looking: it has not happened yet and may not happen.CellaV still needs to establish consistent market adoption and repeat demand.
- Minor point. Forward-looking: it has not happened yet and may not happen.PROTO's second step is expected in January 2027, subject to a favorable safety review.
News Explained
The letter adds that the EU-supported PROTO collaboration was awarded a
Key Figures
- Expected ZEO ownership
- 50%
- Subject to closing and transaction terms
- EIB loan transfer effective date
- November 4, 2026
- Transfer closed and Pluri was released from its EIB obligations
- PROTO trial milestone
- First step successfully completed
- Phase I clinical trial
- Expected second-step start
- January 2027
- PROTO Phase I trial; subject to a favorable safety review
- Non-dilutive grant
- €7.5 million
- Awarded under the Horizon Europe program to the PROTO collaboration
Historical Context
-
Chairman-affiliated entity agreed to acquire the EIB loan; revised loan terms remained pending.
-
Signed agreement contemplated a 50% ZEO stake and exclusive U.S. rights, subject to closing conditions.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
iso 9001 technical
iso 13485 technical
cgmp technical
non-dilutive grant financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Pluri is translating more than two decades of cell-technology, manufacturing and clinical experience into a focused commercial strategy
- Regenerative medicine and the U.S. market are central to this next phase, supported by ZEO, CellaV and PluriCDMO
- Clinical progress, strategic partnerships and greater financial alignment provide multiple avenues to unlock value across Pluri’s asset base
HAIFA, Israel, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq and TASE: PLUR) (“Pluri” or the “Company”) today issued the following letter from Yaky Yanay, President and Chief Executive Officer, following the Company's October 29, 2026 investor update and the November 12, 2026 publication of its first-quarter fiscal 2027 results.
Dear Shareholders,
Following the release of our first-quarter fiscal 2027 results and our recent investor update, I would like to share our perspective on Pluri's progress and the opportunities ahead.
During our October 29 investor update, Pluri's Chairman and major shareholder, Alejandro Weinstein, and I highlighted two significant developments: our strategic agreement with ZEO ScientifiX, designed to accelerate our commercial expansion into the U.S. regenerative medicine market, and the agreement for an entity beneficially owned by Alejandro to acquire Pluri's European Investment Bank loan, representing a strong vote of confidence and an important step toward greater financial flexibility.
These developments support the next phase of Pluri's evolution. Over more than two decades, we have built a strong foundation of proprietary cell technology, advanced manufacturing capabilities, extensive clinical experience, and an intellectual property portfolio of more than 200 patents. We believe these assets represent significant potential value. Our focus now is on translating this foundation into commercial opportunities, with regenerative medicine, longevity, and the U.S. market at the center of our strategy. Our objective is clear: turning our technology, knowledge, and experience into products, partnerships, and sustainable revenue.
Regenerative Medicine and the U.S. Market
We believe regenerative medicine offers Pluri a significant opportunity to apply its experience to products with real medical and commercial relevance. The U.S. is central to this strategy, and Florida is an important starting point. Our objective is to connect credible science and reliable manufacturing with the physicians, patients and channels that can bring appropriate products to market under the applicable regulatory frameworks.
Our signed strategic agreement with ZEO ScientifiX, Inc. (“ZEO”) is designed to provide that connection. ZEO brings existing biologics operations in Florida, products already in market, physician relationships, professional education and sales infrastructure. Pluri brings its cell platform, clinical-development data, intellectual property and manufacturing experience. Subject to closing and the terms of the transaction, Pluri expects to hold
CellaV: Extending Our Cell Science into Regenerative Aesthetics
CellaV is another practical expression of this approach. We have developed placenta-derived and plant-derived active ingredients and professional systems for regenerative skin and hair care. We intend to expand their reach through physician-dispensed channels, clinics and distribution partners, including through the ZEO platform in the U.S. The products and scientific foundation exist; the next stage is to establish consistent market adoption and repeat demand.
Chairman's Vote of Confidence Paves the Way for Greater Financial Flexibility
In October, we announced that an entity beneficially owned by our Chairman, Alejandro Weinstein, entered into an agreement to acquire Pluri's loan from the European Investment Bank (the “EIB”). The loan transfer subsequently closed effective November 4, 2026, and we were released from our obligations to the EIB. We expect to enter into separate agreements with the acquiring entity regarding the settlement of the loan. We view this transaction as a strong expression of long-term confidence in Pluri and an important step toward creating greater alignment and flexibility as we execute our strategy. With our chairman also serving as a principal shareholder, we believe this structure further aligns the interests of our leadership and shareholders as we focus on commercial execution and long-term value creation.
PluriCDMO: Building a Recurring Commercial Business
PluriCDMO allows us to offer development and manufacturing services using infrastructure and experience built over many years. This includes cell-based programs supported by our manufacturing and quality capabilities. Our recently announced ISO 9001 and ISO 13485 Certifications also enable us to extend our offerings to current and new customers requiring those quality standards, in addition to our cGMP cell capabilities.
Unlocking Value from Our Therapeutic Pipeline
Our therapeutic programs continue to represent an important source of value and opportunity for Pluri. Charité in Berlin, recently announced the successful completion of the first step of the PROTO Phase I clinical trial and indicated that the second step is expected to commence in January 2027, subject to a favorable safety review. The study, evaluating PLX-PAD cells in a treatment for mild to moderate knee osteoarthritis, is being conducted as part of the EU-supported PROTO collaboration, which was awarded a
We remain strong believers in the potential of our cells and in the value of the extensive clinical experience and data we have built over the years. As the healthcare and longevity landscape evolves, we are evaluating regulatory pathways and strategic opportunities that could enable us to advance selected assets in our pipeline, including through external funding and partnerships. Our approach will remain focused and disciplined, prioritizing opportunities where the regulatory pathway, capital requirements and potential value creation are well aligned.
Pluri today has more ways to create value from its technology and assets than at any previous point in its development. Our priorities are clear: establish a meaningful commercial presence in regenerative medicine, expand our U.S. market access, grow recurring revenue through PluriCDMO and CellaV, and selectively advance opportunities across our therapeutic and broader asset base.
We are relying on more than two decades of knowledge and data, manufacturing capabilities, clinical experience and intellectual property behind Pluri. Our focus now is on translating that foundation into commercial execution and long-term value. Thank you for your continued support and confidence in Pluri.
Sincerely,
Yaky Yanay
President and Chief Executive Officer
Pluri Inc.
About Pluri Inc.
Pluri Inc. (Nasdaq and TASE: PLUR) develops cell-based technologies and products using its proprietary 3D cell-expansion platform and manufacturing capabilities. The Company's activities include regenerative medicine, longevity, regenerative aesthetics and CDMO services, as well as portfolio companies and strategic partnerships. For more information, visit https://pluri-biotech.com/. View the investor update replay: https://www.youtube.com/watch?v=5ehOwxIUMcs
Safe Harbor Statement
This press release contains express or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. federal securities laws. For example, Pluri is using forward-looking statements when it discusses its strategy and plans to translate its cell technology, manufacturing capabilities, clinical experience and intellectual property into commercial opportunities; its plans to establish a commercial presence in regenerative medicine, expand its access to the U.S. market and grow recurring revenue through PluriCDMO and CellaV; the anticipated benefits of, and Pluri’s ability to complete and implement the transactions contemplated by, its agreement with ZEO, including Pluri’s expected ownership of
The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the possibility that Pluri’s commercialization strategy is delayed, unsuccessful or does not result in anticipated revenues or other benefits; the possibility that the transactions contemplated by the agreement with ZEO are delayed or do not close; the possibility that the anticipated operational, commercial and strategic benefits of the ZEO transaction are not realized; Pluri’s and ZEO’s ability to obtain sufficient financing and successfully implement the contemplated operating and commercialization plans; the possibility that CellaV’s products do not achieve consistent market adoption or repeat demand; the possibility that PluriCDMO does not attract additional customers, programs or revenue; the inability of Pluri to reach definitive agreements regarding the settlement of the transferred loan, or to obtain terms that provide the anticipated financial flexibility; the availability of external funding and strategic partners for Pluri’s therapeutic programs; the timing and results of clinical trials and regulatory review; the Company's ability to successfully execute its commercialization and strategic initiatives; changes in economic, business, market or regulatory conditions; inability to retain or attract key employees; increased competition, loss of market share or pricing pressure; inability to timely develop and introduce new technologies, products and applications; and other risks and uncertainties that may affect the Company's business. Except as otherwise required by law, Pluri undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
For a more detailed description of the risks and uncertainties affecting Pluri, reference is made to Pluri's reports filed from time to time with the Securities and Exchange Commission.
Contact
investor.relations@pluri-biotech.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Pluri's ZEO ScientifiX agreement involve?
Pluri expects to hold 50% of ZEO, subject to closing and transaction terms. The signed agreement is intended to support U.S. regenerative medicine expansion by combining ZEO's existing Florida biologics operations, physician relationships and sales infrastructure with Pluri's cell platform and manufacturing experience.
Has Pluri's European Investment Bank loan been settled?
The loan was transferred to an entity beneficially owned by Chairman Alejandro Weinstein effective November 4, 2026, releasing Pluri from its EIB obligations. Pluri expects to enter into separate agreements with the acquiring entity regarding settlement of the loan; the transfer is not a disclosed completed settlement with that entity.